4/18
07:30 am
abus
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
Low
Report
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
4/4
09:06 am
abus
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $4.00 price target on the stock.
Medium
Report
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $4.00 price target on the stock.
4/4
08:36 am
abus
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna [Financial Post (Toronto, Ontario, Canada)]
4/4
08:30 am
abus
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
Low
Report
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
4/1
12:57 pm
abus
Is Arbutus Biopharma (NASDAQ:ABUS) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]
Low
Report
Is Arbutus Biopharma (NASDAQ:ABUS) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]
3/20
08:33 am
abus
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments [Yahoo! Finance]
Neutral
Report
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments [Yahoo! Finance]
3/8
07:52 am
abus
Arbutus to Participate in Two Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Arbutus to Participate in Two Upcoming Investor Conferences [Yahoo! Finance]
3/8
07:30 am
abus
Arbutus to Participate in Two Upcoming Investor Conferences
Low
Report
Arbutus to Participate in Two Upcoming Investor Conferences
3/3
07:58 am
abus
Arbutus Biopharma Corporation (NASDAQ:ABUS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]
Low
Report
Arbutus Biopharma Corporation (NASDAQ:ABUS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]
3/2
07:54 am
abus
Analysts Just Made A Major Revision To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenue Forecasts [Yahoo! Finance]
Low
Report
Analysts Just Made A Major Revision To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenue Forecasts [Yahoo! Finance]
3/1
08:32 am
abus
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/1
08:13 am
abus
Arbutus Biopharma Co. (NASDAQ: ABUS) had its price target lowered by analysts at HC Wainwright from $6.00 to $5.00. They now have a "buy" rating on the stock.
Low
Report
Arbutus Biopharma Co. (NASDAQ: ABUS) had its price target lowered by analysts at HC Wainwright from $6.00 to $5.00. They now have a "buy" rating on the stock.
3/1
08:13 am
abus
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Low
Report
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
2/29
08:08 am
abus
Arbutus Biopharma Corp (ABUS) Reports Year-End Financial Results and Progress in Clinical Trials [Yahoo! Finance]
Medium
Report
Arbutus Biopharma Corp (ABUS) Reports Year-End Financial Results and Progress in Clinical Trials [Yahoo! Finance]
2/29
07:42 am
abus
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
2/29
07:38 am
abus
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update [Financial Post (Toronto, Ontario, Canada)]
2/29
07:30 am
abus
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
Low
Report
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
2/26
02:57 am
abus
Antisense and RNAi Therapeutics Market Size & Share Envisaged To Reach USD 18.43 Billion By 2032, at 17.8% CAGR Growth: Polaris Market Research [Yahoo! Finance]
Neutral
Report
Antisense and RNAi Therapeutics Market Size & Share Envisaged To Reach USD 18.43 Billion By 2032, at 17.8% CAGR Growth: Polaris Market Research [Yahoo! Finance]
2/15
07:30 am
abus
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
Low
Report
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
2/9
04:13 am
abus
Global Lipid Nanoparticle Manufacturing Market Projects Robust Growth from 2023 to 2035 as Nanomedicine Delivery Advances [Yahoo! Finance]
Medium
Report
Global Lipid Nanoparticle Manufacturing Market Projects Robust Growth from 2023 to 2035 as Nanomedicine Delivery Advances [Yahoo! Finance]
2/2
10:44 am
abus
The past three years for Arbutus Biopharma (NASDAQ:ABUS) investors has not been profitable [Yahoo! Finance]
Medium
Report
The past three years for Arbutus Biopharma (NASDAQ:ABUS) investors has not been profitable [Yahoo! Finance]
1/30
05:49 pm
abus
POWL, AMSC and MANH are among after hour movers [Seeking Alpha]
Medium
Report
POWL, AMSC and MANH are among after hour movers [Seeking Alpha]